globenewswire.com · 2 jul

Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 clinical trials evaluating zoldonrasib, its oral RAS(ON) G12D-selective covalent inhibitor, in combination regimens for patients with RAS G12D metastatic pancreatic ductal adenocarcinoma (PDAC).

fool.com · 1 jul

Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd.

Revolution Medicines' cancer drugs in development could establish new standards of care in some niches. The biotech company may launch its leading candidate within the next year.

globenewswire.com · 24 jun

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

REDWOOD CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that four oral and poster presentations highlighting data from its RAS(ON) pipeline will be featured at the 2026 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress, taking place July 1–4, 2026 in Munich, Germany.

zacks.com · 24 jun

RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib

Revolution Medicines launches a phase III study of zoldonrasib plus chemotherapy in first-line metastatic PDAC harboring RAS G12D mutations.

247wallst.com · 24 jun

After Apogee, 3 More Biotech Buyout Targets Wall Street Can't Stop Watching

Biotech M&A is back in the spotlight. Big Pharma faces patent cliffs over the next several years, and recent dealmaking, including the AbbVie (NYSE: ABBV | ABBV Price Prediction) acquisition of Apogee Therapeutics, signals buyers are willing to pay up for de-risked clinical assets in oncology, obesity, and cell therapy.

globenewswire.com · 22 jun

Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.

Steve Kelsey, president, R&D, to transition to senior advisor to CEO ahead of planned retirement in January 2027 Company announces new R&D leadership structure to support continued execution of strategy REDWOOD CITY, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Steve Kelsey, M.D.

seekingalpha.com · 13 jun

Revolution Medicines: Strong Data, Big Market (Rating Upgrade)

Revolution Medicines is upgraded to buy as Daraxonrasib delivers practice-changing Phase 3 data in pancreatic ductal adenocarcinoma (PDAC). RVMD's $4B pro forma liquidity supports over two years of aggressive clinical expansion, with cash burn focused on value-driving trials and regulatory submissions. Daraxonrasib's Phase 3 results show a 60% reduction in risk of death and doubled median overall survival in metastatic PDAC, supporting a multi-billion-dollar opportunity.

fool.com · 11 jun

Can Revolution Medicines Be a Game-Changer Stock?

Revolution Medicines' promising pancreatic cancer therapy could be approved later this year. The clinical-stage company has more than $4 billion in cash to develop and market its drugs.